JPRN-jRCT2080223969已完成2 期
A Phase 2, randomized, double-blind, cross-over study of S-600918 in subjects with refractory/unexplained chronic cough
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Main inclusion criteria
- •Subjects with refractory/unexplained chronic cough continuing for 6 months or more
排除标准
- •Main exclusion criteria
- •Smokers or subjects who started smoking cessation within the last 6 months or former smokers with a pack/year history greater than 20 pack-years
研究者
相似试验
进行中（未招募）
1 期
A Phase II, double-blind, randomized, cross-over, international,multicentre study to evaluate the analgesic efficacy of 3 weeks oraladministration of AZD4282 300 mg b.i.d. compared with placebo inposttraumatic neuralgiaDiagnostic of Post Traumatic NeuralgiaEUCTR2004-004907-39-DKAstraZeneca AB60
进行中（未招募）
1 期
A Phase II, double-blind, randomized, cross-over, international,multicentre study to evaluate the analgesic efficacy of 3 weeks oraladministration of AZD4282 300 mg b.i.d. compared with placebo inpostherpetic neuralgiaDiagnosis of postherpetic neuralgiaEUCTR2004-004908-21-DKAstraZeneca AB60
进行中（未招募）
不适用
A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensitivity in GERD patients with a partial response to PPI treatment - naGastroesophageal Reflux Disease (GERD) is the intended indicationMedDRA version: 9.1Level: LLTClassification code 10017924Term: Gastroesophageal refluxEUCTR2008-007420-26-DKAstraZeneca AB30
进行中（未招募）
不适用
A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensitivity in GERD patients with a partial response to PPI treatment - naEUCTR2008-007420-26-SEAstraZeneca AB30
进行中（未招募）
不适用
Clinical Trial, Phase II, randomized, double-blind, placebo-controlled, 1-way over with 2 treatment periods of 40 weeks duration.Applicants: Research Group CTS546. IBIMA. Regional University Hospital. Málaga.Subjects: Patients above 55 years with depressive disorders.EUCTR2013-004276-35-ESHospital Regional Universitario. IBIMA